If you have been told your joint is worn but are not ready — or not suited — for surgery, the options can feel limited. The ChondroFiller injection is one approach worth understanding clearly: a non-surgical, outpatient procedure that places a collagen scaffold into the joint to support the body's own repair processes. This article explains what it is, how it works, and what the evidence currently suggests.

Why Cartilage Struggles to Heal

Articular cartilage lines the ends of bones, enabling smooth movement and absorbing load. Because it has a limited blood supply, it does not readily recover once worn or damaged — which is why even modest defects can cause persistent pain and stiffness. This limited healing capacity is the reason that treatments designed to support or scaffold the repair process are of interest.

What ChondroFiller Is

ChondroFiller is a Class III CE-marked medical device: an acellular (cell-free) type I collagen hydrogel scaffold made by Meidrix Biomedicals in Germany and imported into the UK under prescription. It comes as a two-component sterile syringe that mixes at the point of delivery and gels within approximately three to five minutes once placed in the defect.

The CE Class III marking reflects the rigorous safety and performance assessment the device has undergone. The material itself is derived from highly purified type I collagen; it contains no patient cells and no biological additives. Its role is to provide a three-dimensional matrix into which the patient's own progenitor cells can migrate and, over time, begin producing cartilage-like tissue.

How the ChondroFiller Injection Works

The ChondroFiller injection is a non-surgical, minimally invasive outpatient procedure. It is delivered under ultrasound guidance, typically without general anaesthesia and without theatre. The collagen gel is introduced directly into the cartilage defect, where it self-adheres and begins to gel. Once set, it acts as a supportive scaffold over the worn surface — cushioning the joint and providing a biological environment that may encourage the patient's own progenitor cells to migrate in and begin tissue remodelling.

The mechanism is described as acellular matrix-induced chondrogenesis: the implanted scaffold recruits progenitor cells from the surrounding synovium and subchondral bone, which then populate the matrix and, over a period of months, differentiate into cells capable of producing hyaline-like cartilage. The scaffold is designed to be gradually resorbed and replaced by the newly synthesised tissue over roughly one to two years.

It is best understood as a supportive, joint-preserving injection — not a guaranteed repair, cure, or reversal of arthritis. Responses vary, and the extent of benefit depends on the size and depth of the defect, the condition of surrounding tissue, and individual biology.

What the Evidence Suggests

Clinical experience with ChondroFiller is encouraging but continuing to develop. In the knee, published series report improvements in International Knee Documentation Committee (IKDC) scores of approximately 30 points over 12 to 36 months. MRI-based assessment using MOCART scoring has shown values around 80 and above in knee studies, indicating good defect fill and tissue quality. The device has been used across more than 19,000 units since 2013 with a very low reported complication rate.

Evidence from smaller joints is also developing. A 2023 study of an acellular collagen matrix injection for thumb-base (trapeziometacarpal) osteoarthritis reported improvements in pain and grip strength (Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U., 2023, The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis, Cartilage). These results are promising, but the evidence base for smaller joints is less extensive than for the knee, and results cannot be guaranteed.

Is the ChondroFiller Injection the Right Choice?

The injection is suited to a range of joints — including the knee, hip, ankle, and smaller joints such as the thumb base — but patient selection matters. It is generally considered for cartilage defects (ICRS Grade I to IV) up to approximately 6 cm2 in area where a non-surgical approach is appropriate. Joints that are biomechanically unstable or have significant malalignment may need those issues addressed first or in combination.

Some patients will be better served by a surgical approach. For larger or load-bearing defects where a more comprehensive treatment is needed, the Liquid Cartilage protocol — Professor Paul Lee's keyhole surgical procedure that delivers the ChondroFiller scaffold together with biological adjuncts and, where indicated, the patient's own mesenchymal stem cells — may be the more appropriate pathway. These are distinct options: the ChondroFiller injection is non-surgical; Liquid Cartilage is keyhole surgery performed in theatre. A specialist assessment is needed to determine which, if either, is suitable.

Conclusion

ChondroFiller uses type I collagen technology to support a worn joint, providing a scaffold that may help ease symptoms and support tissue remodelling over time. It is not a cure. Evidence from published series is encouraging, but responses vary and benefits cannot be promised. For advice tailored to your situation, the London Cartilage Clinic offers individual assessment with realistic expectations — contact the clinic to arrange a consultation.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.